# Retatrutide Clinical Trial References and Citations | Doctor Retatrutide

> Full citation list for the retatrutide clinical literature: Phase 2 NEJM and Lancet trials, TRIUMPH Phase 3 design, MASLD, kidney, cardiovascular, and pharmacokinetics studies.

## References

[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
[2] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02033-5/abstract
[3] Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract
[4] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10(1):78. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[5] Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(9):2572-2580. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Abouelmagd AA, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):364-373. https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
[7] Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open. 2024;23:100321. https://pmc.ncbi.nlm.nih.gov/articles/PMC11420505/
[8] Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):668-678. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract
[9] Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025;10(8):2304-2315. https://pmc.ncbi.nlm.nih.gov/articles/PMC12231004/
[10] Kanu C, Boye KS, Poon JL, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025;27(9):4782-4791. https://pubmed.ncbi.nlm.nih.gov/40916752/
[11] Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025;3(1):15. https://pmc.ncbi.nlm.nih.gov/articles/PMC11908972/
[12] Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(5):2098-2110. https://pubmed.ncbi.nlm.nih.gov/41090431/
[13] Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease. Nephrol Dial Transplant. 2025;40(10):1734-1743. https://pubmed.ncbi.nlm.nih.gov/41160422/
[14] Doggrell SA. Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023;32(12):1049-1056. https://pubmed.ncbi.nlm.nih.gov/37947489/
[15] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[16] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. [preclinical energy expenditure section] https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[17] Quimbayo-Cifuentes AF. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. Cureus. 2026;18(1):e104259. https://pmc.ncbi.nlm.nih.gov/articles/PMC13031337/
[18] Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023;32(6):479-485. https://pubmed.ncbi.nlm.nih.gov/37086147/
[19] Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). ClinicalTrials.gov. NCT06383390. 2024. https://clinicaltrials.gov/study/NCT06383390
[20] Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. NCT06662383. 2024. https://clinicaltrials.gov/study/NCT06662383
[21] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. [triple agonism mechanistic review section] https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

---

A cinematic index of the Phase 2 and Phase 3 retatrutide trial record — primary sources only, no clinic, no prescription.